N/A
Completed N=63
Extracellular Matrix Marker of Arrhythmia Risk (EMMA)
Myocardiopathies · Ischemia, Myocardial · Arrythmia · Death, Sudden, Cardiac
Source: ClinicalTrials.gov NCT00376532 ↗
Enrolled (actual)
63
Serious AEs
0.0%
Results posted
Jun 2014
Primary outcomePrimary: MMP-2 — 173493.4; 139012.4 pg/ml
Summary
Assess whether serum levels of MMP 2 and or MMP 9 correlate with episodes of ventricular tachycardia or fibrillation in patients who have implantable cardioverter defibrillator devices.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY MMP-2 |
173493.4; 139012.4 | — |
| PRIMARY MMP-9 |
1033545.8; 680388.5 | — |
Eligibility Criteria
Inclusion Criteria
- LVEF of ≤ 35% measured within 6 months of ICD implantation
- NYHA class II-IV at the time of ICD implantation
- ICD implantation at least 1 year prior to enrollment
Exclusion Criteria
- Status post heart transplant
- Known malignancy in the past 2 years.
- Recent procedure, intervention or surgery within the past 90 days
- Acute MI, CABG, or PTCA/stent within the past 2 months.
- Active rheumatoid arthritis or pulmonary or hepatic fibrosis.
- Taking chronic steroid therapy for a medical condition
- Currently pregnant
- Enrolled in a concurrent study that may confound the results of this study
Data sourced from ClinicalTrials.gov (NCT00376532). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.